Identifying a compound that specifically inhibits DNAJA1/HDJ2 or multiple HSP40/JDPs would accelerate the development of targeted cancer therapy, specifically for cancers expressing misfolded/conformational mutp53. The gene discussed is DNAJA1; the disease is cancer.